Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 2 (February)

1. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
   J Laparoendosc Adv Surg Tech A, 14(6): 335-8. [Abstract] [Full-text]
2. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy.
   Cancer, 103(3): 528-37. [Abstract] [Full-text]
3. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
   Cancer, 103(3): 538-45. [Abstract] [Full-text]
4. Prostate cancer among pesticide applicators: a meta-analysis.
   Int Arch Occup Environ Health, 77(8): 559-70. [Abstract] [Full-text]
5. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI.
   Magn Reson Med, 53(2): 249-55. [Abstract] [Full-text]
6. Establishment and characterization of a human primary prostate carcinoma cell line, HH870.
   Prostate, 63(1): 91-103. [Abstract] [Full-text]
7. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.
   Prostate, 63(1): 81-90. [Abstract] [Full-text]
8. Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells.
   Prostate, 63(1): 65-80. [Abstract] [Full-text]
9. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer.
   Prostate, 63(1): 56-64. [Abstract] [Full-text]
10. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
    Prostate, 63(1): 44-55. [Abstract] [Full-text]
11. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Prostate, 63(1): 19-28. [Abstract] [Full-text]
12. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.
    Prostate, 63(1): 29-43. [Abstract] [Full-text]
13. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Prostate, 63(1): 13-8. [Abstract] [Full-text]
14. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
    Prostate, 63(1): 1-12. [Abstract] [Full-text]
15. Improved signal to noise in high-resolution magic angle spinning total correlation spectroscopy studies of prostate tissues using rotor-synchronized adiabatic pulses.
    Magn Reson Med, 53(1): 41-8. [Abstract] [Full-text]
16. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
    J Pathol, 205(3): 359-76. [Abstract] [Full-text]
17. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994).
    Eur J Cancer, 41(3): 411-5. [Abstract] [Full-text]
18. Novel insights into the implication of the IGF-1 network in prostate cancer.
    Trends Mol Med, 11(2): 52-5. [Abstract] [Full-text]
19. Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways.
    Int J Biochem Cell Biol, 37(4): 707-14. [Abstract] [Full-text]
20. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas.
    Histopathology, 46(2): 202-8. [Abstract] [Full-text]
21. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line.
    J Biol Chem, 280(5): 3817-23. [Abstract] [Full-text]
22. Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.
    J Steroid Biochem Mol Biol, 92(5): 327-44. [Abstract] [Full-text]
23. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
    J Cancer Res Clin Oncol, 131(4): 243-54. [Abstract] [Full-text]
24. Human glutathione S-transferase A1, T1, M1, and P1 polymorphisms and susceptibility to prostate cancer in the Japanese population.
    J Cancer Res Clin Oncol, 131(4): 238-42. [Abstract] [Full-text]
25. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo.
    J Clin Endocrinol Metab, 90(2): 893-903. [Abstract] [Full-text]
26. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer.
    J Clin Endocrinol Metab, 90(2): 657-60. [Abstract] [Full-text]
27. Radiotherapy of prostate cancer with multileaf collimators (MLCs) optimization of the undulating dose distribution at the MLC edge.
    Strahlenther Onkol, 181(2): 108-12. [Abstract] [Full-text]
28. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
    Br J Cancer, 92(3): 488-98. [Abstract] [Full-text]
29. Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process.
    Br J Cancer, 92(3): 503-12. [Abstract] [Full-text]
30. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer.
    Br J Cancer, 92(2): 320-7. [Abstract] [Full-text]
31. Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.
    Br J Cancer, 92(2): 236-40. [Abstract] [Full-text]
32. Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline.
    Br J Cancer, 92(2): 366-75. [Abstract] [Full-text]
33. Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling.
    Br J Cancer, 92(1): 140-6. [Abstract] [Full-text]
34. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer.
    Br J Cancer, 92(2): 376-81. [Abstract] [Full-text]
35. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.
    Br J Cancer, 92(1): 36-40. [Abstract] [Full-text]
36. Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites.
    Mod Pathol, 18(2): 228-34. [Abstract] [Full-text]
37. Magmas expression in neoplastic human prostate.
    J Mol Histol, 36(1): 69-75. [Abstract] [Full-text]
38. Tissue oxygen tension measurements in the Shionogi model of prostate cancer using 19F MRS and MRI.
    MAGMA, 17(3): 288-95. [Abstract] [Full-text]
39. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
    BJU Int, 95(4): 650-4. [Abstract] [Full-text]
40. Brachytherapy-related dysuria.
    BJU Int, 95(4): 597-602. [Abstract] [Full-text]
41. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice.
    BJU Int, 95(4): 545-8. [Abstract] [Full-text]
42. Examining the location and cause of death within 30 days of radical prostatectomy.
    BJU Int, 95(4): 541-4. [Abstract] [Full-text]
43. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
    BJU Int, 95(4): 534-40. [Abstract] [Full-text]
44. An evaluation of urinary function after radical prostatectomy in Japanese men: concordance with definitions of urinary continence.
    BJU Int, 95(4): 530-3. [Abstract] [Full-text]
45. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy.
    BJU Int, 95(4): 509-12. [Abstract] [Full-text]
46. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.
    Oncogene, 24(7): 1138-49. [Abstract] [Full-text]
47. Sexual behaviour, history of sexually transmitted diseases, and the risk of prostate cancer: a case-control study in Cuba.
    Int J Epidemiol, 34(1): 193-7. [Abstract] [Full-text]
48. Sp1 and Sp3 transcription factors upregulate the proximal promoter of the human prostate-specific antigen gene in prostate cancer cells.
    Arch Biochem Biophys, 435(2): 291-302. [Abstract] [Full-text]
49. Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(3): 725-35. [Abstract] [Full-text]
50. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Int J Radiat Oncol Biol Phys, 61(3): 714-24. [Abstract] [Full-text]
51. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
    Int J Radiat Oncol Biol Phys, 61(3): 702-13. [Abstract] [Full-text]
52. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
    Int J Radiat Oncol Biol Phys, 61(3): 695-701. [Abstract] [Full-text]
53. Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis.
    Int J Radiat Oncol Biol Phys, 61(3): 687-94. [Abstract] [Full-text]
54. Gastrointestinal stromal tumor of the prostate.
    Urology, 65(2): 388. [Abstract] [Full-text]
55. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Urology, 65(2): 343-6. [Abstract] [Full-text]
56. Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
    Urology, 65(2): 332-6. [Abstract] [Full-text]
57. Impact of previous surgery on endoscopic extraperitoneal radical prostatectomy.
    Urology, 65(2): 325-31. [Abstract] [Full-text]
58. Transperitoneal versus extraperitoneal approach to laparoscopic radical prostatectomy: an assessment of 156 cases.
    Urology, 65(2): 320-4. [Abstract] [Full-text]
59. Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy.
    Urology, 65(2): 311-5. [Abstract] [Full-text]
60. POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis.
    Biochem Biophys Res Commun, 328(4): 1003-9. [Abstract] [Full-text]
61. Phorbol ester-induced apoptosis of C4-2 cells requires both a unique and a redundant protein kinase C signaling pathway.
    J Biol Chem, 280(7): 5533-41. [Abstract] [Full-text]
62. Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo.
    J Biol Chem, 280(7): 6170-80. [Abstract] [Full-text]
63. Current practice of Gleason grading among genitourinary pathologists.
    Hum Pathol, 36(1): 5-9. [Abstract] [Full-text]
64. Radical prostatectomy for localized prostate cancer in a liver transplant recipient.
    Urol Int, 74(1): 95-6. [Abstract] [Full-text]
65. Robotic-assisted anatomic radical prostatectomy: technical difficulties due to a large median lobe.
    Urol Int, 74(1): 92-4. [Abstract] [Full-text]
66. Prognostic significance of the tumor volume in radical prostatectomy specimens after neoadjuvant hormonal therapy.
    Urol Int, 74(1): 27-31. [Abstract] [Full-text]
67. Importance of transition zone prostate biopsies in patients with gray-zone PSA levels undergoing the ultrasound-guided systematic ten-biopsy regimen for the first time.
    Urol Int, 74(1): 23-6. [Abstract] [Full-text]
68. Prostate needle biopsy: 12 vs. 18 cores -- is it necessary?
    Urol Int, 74(1): 19-22. [Abstract] [Full-text]
69. Usefulness of the (F/T)/PSA density ratio to detect prostate cancer.
    Urol Int, 74(1): 13-8. [Abstract] [Full-text]
70. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
    Cancer, 103(4): 708-16. [Abstract] [Full-text]
71. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.
    Cancer, 103(4): 717-23. [Abstract] [Full-text]
72. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma.
    Int J Cancer, 114(4): 563-71. [Abstract] [Full-text]
73. Lifetime physical activity and prostate cancer risk.
    Int J Cancer, 114(4): 639-42. [Abstract] [Full-text]
74. Morpholino antisense oligomer targeting human midkine: its application for cancer therapy.
    Int J Cancer, 114(3): 490-7. [Abstract] [Full-text]
75. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia.
    Int J Cancer, 114(4): 648-52. [Abstract] [Full-text]
76. Insomnia in men treated with radical prostatectomy for prostate cancer.
    Psychooncology, 14(2): 147-56. [Abstract] [Full-text]
77. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis.
    Proc Natl Acad Sci U S A, 102(7): 2525-30. [Abstract] [Full-text]
78. Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated -7 (mda-7)/interleukin-24 (IL-24) gene.
    Cancer Gene Ther, 12(3): 238-47. [Abstract] [Full-text]
79. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
    Cancer Gene Ther, 12(3): 257-67. [Abstract] [Full-text]
80. A cross-sectional study of the international prostate symptom scores related to age and gender in Dutch adults reporting no voiding complaints.
    Eur Urol, 47(3): 334-9. [Abstract] [Full-text]
81. Diabetes mellitus and the risk of prostate cancer in Italy.
    Eur Urol, 47(3): 313-7; discussion 317. [Abstract] [Full-text]
82. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.
    Eur Urol, 47(3): 308-12. [Abstract] [Full-text]
83. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
    Eur Urol, 47(3): 302-7. [Abstract] [Full-text]
84. Can we obtain better specimens with an end-cutting prostatic biopsy device?
    Eur Urol, 47(3): 297-301. [Abstract] [Full-text]
85. Erythropoietin and erythropoietin receptor expression in human prostate cancer.
    Mod Pathol, 18(3): 421-30. [Abstract] [Full-text]
86. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.
    J Clin Oncol, 23(6): 1192-9. [Abstract] [Full-text]
87. Comparison of proposed frameworks for grouping polychlorinated biphenyl congener data applied to a case-control pilot study of prostate cancer.
    Environ Res, 98(1): 104-13. [Abstract] [Full-text]
88. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.
    Neoplasia, 6(6): 846-53. [Abstract] [Full-text]
89. A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data.
    Neoplasia, 6(6): 697-704. [Abstract] [Full-text]
90. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
    Ann Oncol, 16(3): 419-24. [Abstract] [Full-text]
91. A genomewide linkage analysis for prostate cancer susceptibility genes in families from Germany.
    Eur J Hum Genet, 13(3): 352-60. [Abstract] [Full-text]
92. Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer.
    Cancer Lett, 219(2): 177-82. [Abstract] [Full-text]
93. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer.
    J Pathol, 205(4): 522-9. [Abstract] [Full-text]
94. The association of body mass index and prostate-specific antigen in a population-based study.
    Cancer, 103(5): 1092-5. [Abstract] [Full-text]
95. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
    Cancer, 103(5): 943-51. [Abstract] [Full-text]
96. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
    Gene Ther, 12(5): 407-17. [Abstract] [Full-text]
97. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer.
    Prostate, 62(4): 394-9. [Abstract] [Full-text]
98. Health-related quality of life and treatment outcomes for men with prostate cancer treated by combined external-beam radiotherapy and hormone therapy.
    Int J Clin Oncol, 10(1): 45-50. [Abstract] [Full-text]
99. Clinicopathological features of prostate cancer in Japanese men diagnosed on repeat transrectal ultrasound-guided biopsy.
    Int J Clin Oncol, 10(1): 30-4. [Abstract] [Full-text]
100. Prostate cancer: a significant risk factor for late-life suicide.
     Am J Geriatr Psychiatry, 13(3): 195-201. [Abstract] [Full-text]
101. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
     Mol Ther, 11(3): 348-62. [Abstract] [Full-text]
102. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate.
     J Magn Reson Imaging, 21(3): 258-62. [Abstract] [Full-text]
103. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
     Oncogene, 24(9): 1510-24. [Abstract] [Full-text]
104. A hidden cause of hypokalemic paralysis in a patient with prostate cancer.
     Support Care Cancer, 12(11): 810-2. [Abstract] [Full-text]
105. Immunohistochemical assays in prostatic biopsies processed in Bouin's fixative.
     J Clin Pathol, 58(3): 322-4. [Abstract] [Full-text]
106. Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression.
     J Clin Pathol, 58(3): 290-6. [Abstract] [Full-text]
107. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
     J Clin Oncol, 23(7): 1439-46. [Abstract] [Full-text]
108. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
     Cancer Res, 65(4): 1561-9. [Abstract] [Full-text]
109. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway.
     Cancer Res, 65(4): 1325-34. [Abstract] [Full-text]
110. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.
     Cancer Res, 65(4): 1213-22. [Abstract] [Full-text]
111. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.
     Cancer Res, 65(4): 1164-73. [Abstract] [Full-text]
112. IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men.
     Cancer Epidemiol Biomarkers Prev, 14(2): 403-8. [Abstract] [Full-text]
113. Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer.
     Cancer Epidemiol Biomarkers Prev, 14(2): 397-402. [Abstract] [Full-text]
114. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.
     Cancer Epidemiol Biomarkers Prev, 14(2): 390-6. [Abstract] [Full-text]
115. Chlamydial antibodies and risk of prostate cancer.
     Cancer Epidemiol Biomarkers Prev, 14(2): 385-9. [Abstract] [Full-text]
116. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.
     Radiology, 234(3): 804-14. [Abstract] [Full-text]
117. Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy.
     Radiother Oncol, 74(2): 203-10. [Abstract] [Full-text]
118. Rectal and bladder motion during conformal radiotherapy after radical prostatectomy.
     Radiother Oncol, 74(2): 187-95. [Abstract] [Full-text]
119. Strategies to reduce the systematic error due to tumor and rectum motion in radiotherapy of prostate cancer.
     Radiother Oncol, 74(2): 177-85. [Abstract] [Full-text]
120. The design and testing of a solid phantom for the verification of a commercial 3D seed reconstruction algorithm.
     Radiother Oncol, 74(2): 169-75. [Abstract] [Full-text]
121. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery.
     Radiother Oncol, 74(2): 163-7. [Abstract] [Full-text]
122. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer.
     Radiother Oncol, 74(2): 157-61. [Abstract] [Full-text]
123. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
     Radiother Oncol, 74(2): 137-48. [Abstract] [Full-text]
124. Does inverse planning applied to Iridium192 high dose rate prostate brachytherapy improve the optimization of the dose afforded by the Paris system?
     Radiother Oncol, 74(2): 131-6. [Abstract] [Full-text]
125. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer.
     Int J Urol, 12(2): 182-6. [Abstract] [Full-text]
126. Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life.
     Int J Urol, 12(2): 173-81. [Abstract] [Full-text]
127. Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.
     Int J Urol, 12(2): 166-72. [Abstract] [Full-text]
128. Expression of Na+-dependent citrate transport in a strongly metastatic human prostate cancer PC-3M cell line: regulation by voltage-gated Na+ channel activity.
     J Physiol, 563: 393-408. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.